西藥及生技製藥業在目前是世界各國爭相發展的產業，不管是歐美先進國家或開發中國家、各國莫不以發展生物技術產業為國家未來重要發展方向之一。台灣推展生物產業已有多年的時間，政府制定了許多推動發展西藥及生技製藥業發展的相關法令和政策，但到目前為止台灣在生物技術產業的發展並沒有明顯的成果。主要是因為生物科技產業是一項新興產業、在發展之初其產業的特殊性不易掌握、發展起來較不容易。本研究旨在探討此一產業之現況及未來發展前景，本研究中調查我國西藥及生技製藥業之產業近五年以來之進出口狀況◦並且藉由SWOT分析以及鑽石理論分析我國西藥及生技製藥業之競爭優勢，並由貿易特化係數分析我國西藥及生技製藥業之國際競爭力，及各項產品與國家之交叉國際競爭力分析。分析之結果發現在進出口方面，以出口而言，對澳大利亞之分工係數逐年上升，可加強此ㄧ市場拓展。至於對於美、日、德，因為分工係數介於-1至-0.3之間，應考慮引進其技術，以提升本國之技術水準。

The study aims to investigate the international competition of the biotechnological industry. The biotechnological industry is blooming in the world for several years; our government also has many projects to support this industry. But its progress is still limited. So we hope to investigate the reasons, especially the future of this industry. The present study also tries to uncover the international competition between Taiwan, America, Japan, and the other nations by the analysis of Trade specialization coefficient. The results show that the biotechnological industry of Taiwan is hopeful in the future, during the last five years, the biotechnological industry has much progress compared to some other nations. So this industry must use some new skill to improve in the future.